Health ❯ Healthcare ❯ Drug Development ❯ Regulatory Affairs

FDA Approval

Teclistamab–Daratumumab Delivers Major Survival Gains in Relapsed Myeloma, Phase 3 Data Show

New ASH presentation with NEJM publication propels second‑line consideration, with infection prevention protocols viewed as essential for wider use.

Mixed Phase 3 Outcomes Cloud Future of Regeneron and Sanofi’s COPD Candidate Itepekimab